Home / 2016 (page 7)

Yearly Archives: 2016

Nov. 26, 2016

Happy Thanksgiving from all of us here at Diabetes In Control! Many of us are too old to remember how hard tests were when we were in school. In addition, the way learning works now there is always a good chance you can Google the answer. So, the question that …

Read More »

Question #861

Test Your Knowledge

In 2016, the TYK questions that received the most interest from our readers were those with a personal touch: questions that gave case-study style descriptions of individual patients and their needs. The 5 most popular questions of the year are featured in this issue. Can you guess which of these 2016 TYK questions was the most popular of all? A. Question #814, January 2: Unnamed patient B. Question #817, January 23: Mrs. O'Doole C. Question #823, March 5: Mrs. Hunter D. Question #833, May 14: Mrs. Wilson E. Question #835, May 26: Mr. Fontello

Read More »

Survey Says: Top Polls of 2016

In a year that saw much discussion about new drugs, new devices, and how politics might affect medical care, the surveys you were most interested in were those that touched on the core aspects of care for patients with diabetes. See the five polls that engaged you most.

Read More »

Responding to Surveys

Why do you respond to DIC survey questions? 1. Because the question is interesting 2. Want to share my opinion 3. Want to see what my colleagues think 4. All of the above 5. I usually don't respond

Read More »

Nov. 22, 2016

On Monday, the FDA gave approval to NovoNordisk’s new combination product, Xultophy. This is a combination of the super long-acting insulin degludec and the once daily GLP-1 agonist Liraglutide. The fixed dose combination is given in one to 50 dosing steps to maximize to glycemic control. The super long-acting insulin …

Read More »

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #51: Incretin Physiology in Health and Disease Part 1 of 6

The incretin effect in health: The idea that gastrointestinal factors contribute to the control of postprandial glucose regulation dates back to the beginning of the twentieth century, when Moore and colleagues reported reductions in glucosuria after the oral administration of gut extracts xin patients with juvenile diabetes. Even though it is questionable whether these glucose-lowering effects were really attributable to the incretin activity of the extract (which is unlikely, because most gastrointestinal peptide hormones are inactivated by the gastric acid), this report can be considered as the first description of an incretin-like effect.

Read More »